NASDAQ:ALXO

Alx Oncology Holdings Stock Insider Trading

Healthcare > Biotechnology

Buy ALXO

*Your capital is at risk

$1.94

-0.0100 (-0.513%)

At Close: Jul 31, 2026

ALX Oncology Holdings Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 97.54. In total, the insiders bought 13.26M and sold 71.34K ALXO shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	97.54
● Buy	13.26M shares
● Sell	71.34K shares
74% Buy Activity Negligible or No Correlation
Buy Signal Medium Confidence Feb 02, 2026 Analysis Breakdown: Strongly supported by a very high Insider Power Score of 97.54. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Jan 21, 2025 Buy	Employee Stock Option (right to buy) A-Award	Sandler Alan B. Chief Medical Officer	Officer	100 000 Value: $165.0K
Jan 21, 2025 Buy	Employee Stock Option (right to buy) A-Award	Pons Jaume President & Cso	CEO / President	50 000 Value: $82.5K
Jan 21, 2025 Buy	Employee Stock Option (right to buy) A-Award	Lettmann Jason Chief Executive Officer	CEO / President	478 000 Value: $788.7K
Jan 21, 2025 Buy	Employee Stock Option (right to buy) A-Award	Sandler Alan B. Chief Medical Officer	Officer	100 000 Value: $165.0K
Jan 21, 2025 Buy	Employee Stock Option (right to buy) A-Award	Lettmann Jason Chief Executive Officer	CEO / President	478 000 Value: $788.7K
Jan 21, 2025 Buy	Employee Stock Option (right to buy) A-Award	Pons Jaume President & Cso	CEO / President	50 000 Value: $82.5K
Jan 21, 2025 Buy	Employee Stock Option (right to buy) A-Award	Pinto Shelly SVP, Finance And Cao	Officer	112 000 Value: $184.8K
Jan 21, 2025 Buy	Common Stock J-Other	Shantharam Harish Insider	Other	0 Value: $0
Jan 21, 2025 Buy	Employee Stock Option (right to buy) A-Award	Shantharam Harish Chief Financial Officer	C-Suite Officer	600 000 Value: $990.0K
Jan 21, 2025 Buy	Common Stock	Klencke Barbara Director	Director	0 Value: $0
Jan 21, 2025 Buy	Stock Option (right to buy) A-Award	Klencke Barbara Director	Director	40 400 Value: $66.7K
Jan 21, 2025 Buy	Common Stock J-Other	Takimoto Chris H Insider	Other	0 Value: $0
Jan 21, 2025 Buy	Common Stock (right to buy) A-Award	Takimoto Chris H Director	Director	40 400 Value: $66.7K
Jan 21, 2025 Buy	Stock Option (right to buy) A-Award	Goodman Corey S	Director	40 400 Value: $66.7K
Jan 21, 2025 Buy	Common Stock A-Award	Garland J. Scott Director	Director	40 400 Value: $66.7K
Jan 21, 2025 Buy	Stock Option (right to buy) A-Award	Hemrajani Rekha Director	Director	40 400 Value: $66.7K
Jan 06, 2025 Sell	Common Stock S-Sale	Pinto Shelly Interim CFO	C-Suite Officer	2 221 Value: $4K
Jan 06, 2025 Sell	Common Stock S-Sale	Pinto Shelly Interim CFO	C-Suite Officer	2 221 Value: $4K
Dec 30, 2024 Sell	Common Stock S-Sale	Pinto Shelly Interim CFO	C-Suite Officer	1 426 Value: $2K
Dec 30, 2024 Sell	Common Stock S-Sale	Pons Jaume President & Cso	CEO / President	10 796 Value: $17.1K
Dec 30, 2024 Sell	Common Stock S-Sale	Pons Jaume President & Cso	CEO / President	10 796 Value: $17.1K
Dec 30, 2024 Sell	Common Stock S-Sale	Pinto Shelly Interim CFO	C-Suite Officer	1 426 Value: $2K
Dec 02, 2024 Buy	Common Stock P-Purchase	Hemrajani Rekha Director	Director	30 000 Value: $46.4K
Dec 02, 2024 Buy	Employee Stock Option (right to buy) A-Award	Pinto Shelly Interim CFO	C-Suite Officer	150 000 Value: $249.0K
Dec 02, 2024 Buy	Employee Stock Option (right to buy) A-Award	Lettmann Jason Chief Executive Officer	CEO / President	200 000 Value: $332.0K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT ALX ONCOLOGY HOLDINGS INC.

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hodgkin's lymphoma, as well as a range of solid tumor indications, including head and neck squamous cell c...

Read Full Profile Here